Sparks commentary - SynAct Pharma

Healthcare

Sparks - SynAct Pharma

More on this equity
SynAct Pharma (STO: SYNACT) confirms recruitment on-track in RA trial
Published by Arron Aatkar, PhD

SynAct Pharma has announced that its Phase IIb ADVANCE trial, evaluating lead asset resomelagon in patients with newly diagnosed rheumatoid arthritis (RA), is on-track to complete patient recruitment by end-2025, consistent with prior guided timelines, with 190 out of 240 participants now randomised. ADVANCE has been designed as a 12-week, randomised, placebo-controlled study. It is specifically targeting RA patients with high disease activity who are eligible for methotrexate treatment (the current standard of care). Top-line results are anticipated in Q126, and as this is the lead programme, it represents an important upcoming inflection point for SynAct.

Latest